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Background: Liposarcoma is the most common type of soft tissue sarcoma (STS). It is divided into five groups
according to histological pattern: well-differentiated, myxoid, round cell, pleomorphic, and dedifferentiated.
Dedifferentiated liposarcoma most commonly occurs in the retroperitoneum, while an intraperitoneal location is
extremely rare. Only seven cases have been reported in literature. Many pathologists recognize that a large number
of intra-abdominal poorly differentiated sarcomas are dedifferentiated liposarcomas. We report a case initially
diagnosed as undifferentiated sarcoma that was reclassified as intraperitoneal dedifferentiated liposarcoma showing
an amplification of the MDM2 gene.
Case presentation: A 59-year-old woman with abdominal pain and constipation was referred to the Department
of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy, in November 2012. On physical
examination, a very large firm mass was palpable in the meso-hypogastrium. Computed tomography (CT) scan
showed a heterogeneous density mass (measuring 10 × 19 cm) that was contiguous with the mesentery and
compressed the third part of the duodenum and jejunum.
At laparotomy, a large mass occupying the entire abdomen was found, adhering to the first jejunal loop and
involving the mesentery. Surgical removal of the tumor along with a jejunal resection was performed because the
first jejunal loop was firmly attached to the tumor.
Macroscopic examination showed a solid, whitish, cerebroid, and myxoid mass, with variable hemorrhage and
cystic degeneration, measuring 26 × 19 × 5 cm. Microscopic examination revealed two main different morphologic
patterns: areas with spindle cells in a myxoid matrix and areas with pleomorphic cells. The case was initially diagnosed
as undifferentiated pleomorphic sarcoma. Histological review showed areas of well-differentiated liposarcoma.
Fluorescence in situ hybridization (FISH) analysis was performed and demonstrated an amplification of the MDM2 gene.
Definitive diagnosis was intraperitoneal dedifferentiated liposarcoma.
No adjuvant therapy was given, but 5 months after laparotomy, the patient presented with a locoregional recurrence
and chemotherapy with high-dose ifosfamide was started.
Conclusions: No guidelines are available for the management of intraperitoneal dedifferentiated liposarcoma. We
report this case to permit the collection of a larger number of cases to improve understanding and management of this
tumor. Moreover, this study strongly suggests that poorly differentiated sarcomas should prompt extensive sampling to
demonstrate a well-differentiated liposarcoma component and, if possible, FISH analysis.
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Soft tissue sarcoma (STS) is a rare mesenchymal tumor
arising from non-epithelial connective tissue sources. The
incidence of STS is approximately 4 to 5/100,000/year in
Europe [1-3]. Liposarcoma is the most common STS, and
can bedivided into five groups according to histological pat-
tern: well-differentiated, myxoid, round cell, pleomorphic,
and dedifferentiated [4-7].
Dedifferentiated liposarcoma is a variant of liposarcoma
with a worse prognosis and it most commonly occurs in
the retroperitoneum, while an intraperitoneal location is
extremely rare. Five cases of dedifferentiated liposarcoma
in small bowel mesentery have been described [8]. More-
over, a case of dedifferentiated liposarcoma has been doc-
umented in the sigmoid mesocolon [9]. Another case
reported in the literature was located at an intraperitoneal
location [10]. Many pathologists recognize that a large
number of intra-abdominal poorly differentiated sarcomas
are dedifferentiated liposarcomas [11].
We report herein a case initially diagnosed as undiffer-
entiated sarcoma that was reclassified as intraperitoneal
dedifferentiated liposarcoma showing an amplification of
the murine double minute 2 (MDM2) gene, in order to
emphasize that in most cases of undifferentiated sarco-
mas, a specific line of differentiation can be demonstrated.
Case presentation
A 59-year-old woman with Parkinson’s disease, who com-
plained of abdominal pain and constipation, was referred to
the Department of Advanced Biomedical Sciences, Univer-
sity of Naples Federico II, Naples, Italy, in November 2012.
On physical examination, a firm mass was palpable in the
meso-hypogastrium. There were no laboratory abnormal-
ities, except hyposideremia (29 mcg/dL) and a positive testFigure 1 CT scans. (A) Coronal CT image demonstrating the extent of the m
with lateral displacement of the bowel.result for HBsAg. Tumor markers such as carcinoembryo-
nic antigen (CEA), CA19-9, and CA-125 were within their
normal ranges.
Ultrasound revealed a very large mass with a com-
plex echogenicity, almost completely occupying the lower
quadrants of the abdomen. Computed tomography (CT)
scan showed that the mass occupied the entire meso-
hypogastric region, had heterogeneous density, involved the
mesentery, and displaced the small bowel loops (Figure 1).
Moreover, it also showed a complicated diverticulitis at the
sigmoid colon with a pericolic abscess.
At laparotomy a very large mass was found with dense
adhesions to the mesentery and sigmoid colon. The tumor
seemed to arise from the first jejunal loop. A jejunal resec-
tion with mass excision and a gastrojejunostomy was per-
formed (Figure 2). We also made an anterior resection
with primary anastomosis for the sigmoid complicated di-
verticulitis, together with cholecystectomy for cholelithia-
sis and appendicectomy.
Macroscopic examination of the specimen showed a
very large, solid, whitish, cerebroid, and myxoid mass,
with variable hemorrhage and cystic degeneration, a het-
erogeneous cut surface, and measuring approximately
26 × 19 × 5 cm. At an extremity there was a small intes-
tinal resection of 10 cm that was on the serous surface
of the tumor (Figure 3A).
Microscopic examination revealed two main morpho-
logic patterns: first, areas that were less crowded with
spindle cells in a myxoid matrix (Figure 3B) and occasion-
ally disposed in a storiform pattern; and second, more
crowded areas with pleomorphic cells and atypical mitosis
(Figure 3C). Histological examination also revealed that
the neoplasia reached the muscularis propria region of
the intestine.ass; and (B) CT slice showing the heterogeneous density of the mass
Figure 2 Images of the tumor. (A) The very large tumor; (B) tumor adhering to the small bowel loops; (C) gastrojejunostomy; and (D) the
surgical specimen.
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actin, calretinin, and CD117 (c-Kit) were negative, while
Bcl-2, EMA, and CD99 were positive in the neoplastic cells.
The histopathological diagnosis was of an undifferentiated
pleomorphic sarcoma.Figure 3 Macroscopic and microscopic examination. (A) Heterogeneou
(C) a population of pleomorphic cells.Histological review showed areas of well-differentiated
liposarcoma and the tumor was reclassified as dediffer-
entiated liposarcoma. Moreover, a fluorescence in situ
hybridization (FISH)analysis was performed and demon-
strated an amplification of the MDM2 gene. These findingss cut surface; (B) a population of spindle cells in a myxoid matrix; and
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liposarcoma.Discussion
Intraperitoneal dedifferentiated liposarcomas are rare and,
to our knowledge, only eight cases have been reported to
date (Table 1). Of these cases, patients were aged between
59 and 63 years, and five were female. There were no char-
acteristic complaints at presentation and patients reported
abdominal fullness or pain. The diagnosis of intraperito-
neal dedifferentiated liposarcoma is always late as the dis-
ease remains asymptomatic until progression reaches the
end stages.
AWD, alive with disease; DOD, died of disease; NED,
no evidence of disease; RTX, radiation therapy.
Imaging modalities may help in preoperative diagnosis
of the origin of tumor. However, CT findings may sug-
gest the diagnosis of liposarcoma when the tumor con-
tains areas of fat attenuation, which is less likely to be
seen in higher-grade liposarcomas. Moreover, dedifferen-
tiated liposarcomas demonstrate marked heterogeneity
on magnetic resonance imaging (MRI), with areas of ne-
crosis and heterogeneous contrast enhancement, indis-
tinguishable from other high-grade sarcomas [12-15].
Accurate diagnosis demands an experienced patholo-
gist, the use of immunohistochemistry, and often also
cytogenetics [16,17]. Microscopically, this case resembled
an undifferentiated pleomorphic sarcoma, which could not
be a specific soft tissue tumor but a common morphologic
appearance resulting from tumor progression of various
sarcomas, especially liposarcomas, but also others. Dedif-
ferentiated liposarcomas typically show extensive areas
resembling undifferentiated pleomorphic sarcoma; the diag-
nosis of dedifferentiated liposarcoma is thus reached by
identification of areas of well-differentiated liposarcoma,
but this component can be scarce and therefore can be lost
by sampling or simply not present [18]. Consequently, ded-
ifferentiated liposarcomas may exist without any demon-
strable well-differentiated liposarcoma component.Table 1 Reported cases of intraperitoneal dedifferentiated lip
Reference Age (years)/
gender
Site Size (cm) P
tr
Hasegawa [8] 59/M Mesentery 14 Su
Hasegawa [8] 58/F Mesentery 20 Su
Hasegawa [8] 56/F Mesentery 30 Su
Hasegawa [8] 52/F Mesentery 40 Su
Hasegawa [8] 63/F Mesentery 10 Su
Karaman [10] 62/M Intraperitoneal location 10 Su
Winn [9] 59/M Sigmoid mesocolon 25 Su
Current case report 59/F Intraperitoneal location 26 SuWell-differentiated liposarcomas/atypical lipomatous tu-
mors and dedifferentiated liposarcomas have been cy-
togenetically shown to harbor ring and giant marker
chromosomes consisting of amplicons in the 12q13-15
region, resulting in amplification of several genes, including
most notablyMDM2 [19,20]. IdentifyingMDM2 amplifica-
tion by immunohistochemistry, FISH, quantitative PCR, or
comparative genomic hybridization (CGH) may prove an
adjunctive tool in the diagnosis of lipomatous neoplasms.
This feature can be of remarkable help in reaching the
diagnosis of dedifferentiated liposarcoma, particularly in
cases of poorly differentiated sarcomas for which a specific
line of differentiation cannot be demonstrated, as observed
in this case.
Radical excision of the tumor offers the possibility of
longer survival and a disease-free interval. In all patients
reviewed in the literature, surgical excision was the first
line of treatment of intraperitoneal liposarcoma. The value
of adjuvant chemotherapy has not been established. Post-
operative radiotherapy to the whole tumor bed is not fea-
sible at a tolerable toxicity [21,22]. One patient underwent
adjuvant radiotherapy and was asymptomatic for the 15-
month follow-up period (Table 1).
In terms of recurrence, follow-up information is avail-
able for all cases reported. Only one patient did not have
recurrence. Of the eight patients, three died of disease.
Conclusions
In summary, the rarity of intraperitoneal dedifferentiated
liposarcoma makes it difficult to investigate clinical char-
acteristics, therapy, and outcomes. Differential diagnosis of
this tumor can be very difficult because the histological
examination does not demonstrate a specific line of differ-
entiation. Therefore, in cases initially diagnosed as poorly
differentiated sarcomas, extensive sampling and an analysis
of MDM2 amplification using FISH are recommended.
Surgery is the main treatment and the role of adjuvant
therapy is widely debated.In order to improve overall un-
derstanding of the intraperitoneal liposarcoma, it is useful








rgery No 72 DOD, 6 years, 1 month
rgery No 50 NED, 9 years, 7 month
rgery No 12 DOD, 6 years, 2 months
rgery No 159 DOD, 20 years, 3 months
rgery No 124 AWD, 15 years, 2 month
rgery RTX 0 AWD, 1 year, 3 months
rgery No 30 NED, 4 years, 6 months
rgery No 5 AWD, 7 months
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